ES2382946T3 - Virus de la encefalitis Japonesa atenuado - Google Patents
Virus de la encefalitis Japonesa atenuado Download PDFInfo
- Publication number
- ES2382946T3 ES2382946T3 ES05014317T ES05014317T ES2382946T3 ES 2382946 T3 ES2382946 T3 ES 2382946T3 ES 05014317 T ES05014317 T ES 05014317T ES 05014317 T ES05014317 T ES 05014317T ES 2382946 T3 ES2382946 T3 ES 2382946T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- vaccine
- vero
- protein
- attenuated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 20
- 241000700605 Viruses Species 0.000 title claims description 195
- 206010014599 encephalitis Diseases 0.000 title description 2
- 229960005486 vaccine Drugs 0.000 claims abstract description 102
- 210000003501 vero cell Anatomy 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 47
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000002671 adjuvant Substances 0.000 claims abstract description 12
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 8
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims abstract description 6
- 201000005807 Japanese encephalitis Diseases 0.000 claims abstract description 6
- 230000000415 inactivating effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 230000002779 inactivation Effects 0.000 description 17
- 150000001413 amino acids Chemical group 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 238000006386 neutralization reaction Methods 0.000 description 12
- 239000012228 culture supernatant Substances 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940037003 alum Drugs 0.000 description 7
- 239000013553 cell monolayer Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000005199 ultracentrifugation Methods 0.000 description 7
- 101710204837 Envelope small membrane protein Proteins 0.000 description 6
- 101710088839 Replication initiation protein Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940031551 inactivated vaccine Drugs 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000007327 Protamines Human genes 0.000 description 3
- 108010007568 Protamines Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229950008679 protamine sulfate Drugs 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000012007 large scale cell culture Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- -1 Bayol Chemical class 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101000600488 Pinus strobus Putative phosphoglycerate kinase Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 239000004234 Yellow 2G Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical class O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220081925 rs756442818 Human genes 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR4200297 | 1997-08-28 | ||
| KR19970042002 | 1997-08-28 | ||
| KR4200197 | 1997-08-28 | ||
| KR19970042001 | 1997-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2382946T3 true ES2382946T3 (es) | 2012-06-14 |
Family
ID=26633032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05014317T Expired - Lifetime ES2382946T3 (es) | 1997-08-28 | 1998-08-25 | Virus de la encefalitis Japonesa atenuado |
| ES98941885T Expired - Lifetime ES2281929T3 (es) | 1997-08-28 | 1998-08-25 | Virus de la encefalitis japonesa atenuado adaptado a las celulas vero y vacuna contra la encefalitis japonesa. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98941885T Expired - Lifetime ES2281929T3 (es) | 1997-08-28 | 1998-08-25 | Virus de la encefalitis japonesa atenuado adaptado a las celulas vero y vacuna contra la encefalitis japonesa. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6309650B1 (https=) |
| EP (2) | EP1025209B1 (https=) |
| JP (1) | JP4161017B2 (https=) |
| KR (1) | KR100314404B1 (https=) |
| CN (1) | CN1142271C (https=) |
| AU (1) | AU748730B2 (https=) |
| CA (1) | CA2301000C (https=) |
| DE (2) | DE69837211T2 (https=) |
| DK (2) | DK1025209T3 (https=) |
| ES (2) | ES2382946T3 (https=) |
| FR (1) | FR09C0037I2 (https=) |
| MY (1) | MY129773A (https=) |
| NL (1) | NL300391I2 (https=) |
| NZ (1) | NZ503522A (https=) |
| WO (1) | WO1999011762A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000083657A (ja) * | 1998-07-13 | 2000-03-28 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスワクチン |
| US6841374B1 (en) | 1998-10-05 | 2005-01-11 | Research Foundation For Microbial Diseases Of Osaka University | Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same |
| DK2251419T3 (da) * | 1999-04-22 | 2012-07-02 | Us Agriculture | Porcint reproduktions- og respirations-syndrom-vaccine baseret på isolat JA-142 |
| WO2001076624A1 (en) * | 2000-04-07 | 2001-10-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Inactivated japanese b encephalitis vaccine and process for producing the same |
| WO2003002069A2 (en) * | 2001-06-29 | 2003-01-09 | Becton, Dickinson And Company | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| JP2007068401A (ja) * | 2003-08-07 | 2007-03-22 | Chemo Sero Therapeut Res Inst | 西ナイルウイルスワクチン |
| NZ548495A (en) * | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| CN100340596C (zh) * | 2004-05-20 | 2007-10-03 | 佛山市顺德区汉达精密电子科技有限公司 | 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法 |
| DK1869171T4 (en) * | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| CA2676775A1 (en) * | 2007-01-31 | 2008-09-25 | Sanofi Pasteur Biologics Co. | Flavivirus vaccine vector against influenza virus |
| KR20160003301A (ko) * | 2007-12-26 | 2016-01-08 | 기타사토 다이이치 산쿄 백신 가부시키가이샤 | 안정하게 장기간 보존할 수 있는 일본뇌염 백신의 제조방법 및 그 백신의 용도 |
| EP2298344B1 (en) * | 2008-06-04 | 2016-08-17 | The Chemo-Sero-Therapeutic Research Institute | Use of inactivated japanese encephalitis virus particle as adjuvant |
| KR101622738B1 (ko) * | 2008-07-30 | 2016-05-19 | 히사미쓰 세이야꾸 가부시키가이샤 | 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법 |
| WO2010137036A2 (en) * | 2009-05-25 | 2010-12-02 | Panacea Biotec Ltd | Novel japanese encephalitis vaccine and method of manufacturing the same |
| KR101144993B1 (ko) * | 2009-06-18 | 2012-06-27 | 대한민국 | 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원 |
| ES2647882T3 (es) | 2011-12-06 | 2017-12-27 | Valneva Austria Gmbh | Compuestos de aluminio para su uso en productos terapéuticos y vacunas |
| US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
| RU2706693C2 (ru) * | 2013-09-14 | 2019-11-20 | Бхарат Байотек Интернэшнл Лимитед | Вирусная вакцина и способы ее производства |
| CN105695424B (zh) * | 2015-04-01 | 2019-06-14 | 中国食品药品检定研究院 | 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗 |
| EP3393509B1 (en) | 2015-12-23 | 2024-02-28 | Valneva SE | Virus purification |
| EP3403671B1 (en) * | 2016-01-15 | 2023-06-07 | KM Biologics Co., Ltd. | Vaccine containing immobilized virus particles |
| WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
| EP3684404A1 (en) | 2017-09-21 | 2020-07-29 | Valneva SE | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 |
| MX2020004543A (es) | 2017-11-03 | 2020-09-18 | Takeda Vaccines Inc | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. |
| CN116983398A (zh) | 2017-11-30 | 2023-11-03 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物以及其使用方法 |
| CN110684747B (zh) | 2018-07-06 | 2024-05-24 | 厦门大学 | 灭活及保存呼吸道合胞病毒的方法 |
| WO2020045368A1 (ja) * | 2018-08-27 | 2020-03-05 | マイキャン・テクノロジーズ株式会社 | 不死化単球細胞および誘導細胞を用いた抗感染症薬，ワクチンなどの評価方法 |
| EP3895729A1 (en) | 2020-03-01 | 2021-10-20 | Valneva Austria GmbH | Cpg-adjuvanted sars-cov-2 virus vaccine |
| AU2021229710A1 (en) | 2020-03-01 | 2022-10-06 | Dynavax Technologies Corporation | CPG-adjuvanted SARS-CoV-2 virus vaccine |
| WO2021178306A1 (en) | 2020-03-01 | 2021-09-10 | Dynavax Technologies Corporation | Coronavirus vaccines comprising a tlr9 agonist |
| EP4114456A1 (en) | 2020-03-06 | 2023-01-11 | The Colorado State University Research Foundation | Production of vaccines comprising inactivated sars-cov-2 viral particles |
| TW202203967A (zh) | 2020-04-06 | 2022-02-01 | 奧地利商瓦爾尼瓦奧地利有限責任公司 | 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗 |
| WO2023148256A1 (en) | 2022-02-02 | 2023-08-10 | Valneva Austria Gmbh | Inactivated sars-cov-2 virus vaccine |
| EP4428231A4 (en) * | 2022-04-20 | 2025-11-19 | Korea Nat Institute Of Health | GENOTYPE 5 OF HIGH-TIRES JAPANESE ENCEPHALITIS VIRUS AND ITS USE |
| EP4652265A1 (en) | 2023-01-18 | 2025-11-26 | Valneva Austria GmbH | Process for virus production in a bioreactor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2704258B2 (ja) * | 1987-10-31 | 1998-01-26 | 日本臓器製薬株式会社 | 組み換えワクチニアウイルス |
| GB8821656D0 (en) * | 1988-09-15 | 1988-10-12 | Health Lab Service Board | Pharmaceutical compositions for eliciting immunostimulant effect |
| JPH085803B2 (ja) * | 1988-11-10 | 1996-01-24 | 武田薬品工業株式会社 | 日本脳炎ワクチンの製造法 |
| EP0562136A1 (en) | 1992-03-24 | 1993-09-29 | Division Of Microbiology, Kyoto Biken Laboratories, Inc. | Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases |
| US6010894A (en) * | 1997-06-13 | 2000-01-04 | Research Development Foundation | Method of screening for attenuating viruses |
-
1998
- 1998-08-25 EP EP98941885A patent/EP1025209B1/en not_active Expired - Lifetime
- 1998-08-25 DK DK98941885T patent/DK1025209T3/da active
- 1998-08-25 ES ES05014317T patent/ES2382946T3/es not_active Expired - Lifetime
- 1998-08-25 DE DE69837211T patent/DE69837211T2/de not_active Expired - Lifetime
- 1998-08-25 JP JP2000508774A patent/JP4161017B2/ja not_active Expired - Lifetime
- 1998-08-25 CN CNB988097974A patent/CN1142271C/zh not_active Expired - Lifetime
- 1998-08-25 ES ES98941885T patent/ES2281929T3/es not_active Expired - Lifetime
- 1998-08-25 CA CA002301000A patent/CA2301000C/en not_active Expired - Lifetime
- 1998-08-25 NZ NZ503522A patent/NZ503522A/en not_active IP Right Cessation
- 1998-08-25 EP EP05014317A patent/EP1604685B1/en not_active Expired - Lifetime
- 1998-08-25 DE DE122009000037C patent/DE122009000037I2/de active Active
- 1998-08-25 WO PCT/KR1998/000259 patent/WO1999011762A1/en not_active Ceased
- 1998-08-25 DK DK05014317.1T patent/DK1604685T3/da active
- 1998-08-25 AU AU90047/98A patent/AU748730B2/en not_active Expired
- 1998-08-25 US US09/486,392 patent/US6309650B1/en not_active Expired - Lifetime
- 1998-08-26 MY MYPI98003899A patent/MY129773A/en unknown
- 1998-08-27 KR KR1019980035007A patent/KR100314404B1/ko not_active Expired - Fee Related
-
2009
- 2009-06-10 NL NL300391C patent/NL300391I2/nl unknown
- 2009-08-14 FR FR09C0037C patent/FR09C0037I2/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU748730B2 (en) | 2002-06-13 |
| DE122009000037I1 (de) | 2009-11-05 |
| US6309650B1 (en) | 2001-10-30 |
| KR100314404B1 (ko) | 2002-10-12 |
| EP1604685A2 (en) | 2005-12-14 |
| EP1025209A1 (en) | 2000-08-09 |
| FR09C0037I2 (fr) | 2021-11-05 |
| MY129773A (en) | 2007-04-30 |
| EP1604685A3 (en) | 2006-07-05 |
| JP4161017B2 (ja) | 2008-10-08 |
| NL300391I2 (nl) | 2009-11-02 |
| EP1604685B1 (en) | 2012-02-22 |
| FR09C0037I1 (https=) | 2009-09-25 |
| CA2301000C (en) | 2003-07-08 |
| DE69837211T2 (de) | 2007-12-06 |
| CN1272879A (zh) | 2000-11-08 |
| DK1604685T3 (da) | 2012-06-18 |
| CN1142271C (zh) | 2004-03-17 |
| ES2281929T3 (es) | 2007-10-01 |
| AU9004798A (en) | 1999-03-22 |
| JP2001514844A (ja) | 2001-09-18 |
| DE69837211D1 (de) | 2007-04-12 |
| WO1999011762A1 (en) | 1999-03-11 |
| EP1025209B1 (en) | 2007-02-28 |
| DK1025209T3 (da) | 2007-06-25 |
| DE122009000037I2 (de) | 2011-06-16 |
| KR19990023955A (ko) | 1999-03-25 |
| CA2301000A1 (en) | 1999-03-11 |
| NZ503522A (en) | 2001-06-29 |
| NL300391I1 (nl) | 2009-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2382946T3 (es) | Virus de la encefalitis Japonesa atenuado | |
| US10548964B2 (en) | Antigens and vaccines directed against human enteroviruses | |
| Wu et al. | Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus | |
| ES2374131T3 (es) | Flavivirus quiméricos avirulentos e inmunógenos. | |
| HK1251492A1 (en) | Vaccines directed against human enteroviruses | |
| UA126548C2 (uk) | Вакцинна композиція для профілактики абровірусних інфекцій | |
| US20150056244A1 (en) | Antigens and Vaccines Directed Against Human Enteroviruses | |
| US10590174B2 (en) | Genomic sequences encoding for an attenuated mutant Zika virus | |
| JP5657204B2 (ja) | デングウイルスのカプシドタンパク質を有する、デングウイルスに対する防御反応を誘導することができる医薬品組成物 | |
| CN113186171B (zh) | 一种黄病毒属病毒的减毒病毒及其用途 | |
| TWI228147B (en) | An attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine | |
| Pyo Hong et al. | Preparation of a purified, inactivated Japanese encephalitis (JE) virus vaccine in Vero cells | |
| JPH0923880A (ja) | 高度に弱毒化された組換え日本脳炎ウイルスを産生する感染性日本脳炎ウイルスｃＤＮＡクローンおよびそのワクチン |